These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24849396)

  • 1. Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs.
    Diel R; Lampenius N
    Pharmacoeconomics; 2014 Jul; 32(7):617-26. PubMed ID: 24849396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
    Diel R; Hittel N; Schaberg T
    Respir Med; 2015 May; 109(5):632-41. PubMed ID: 25862597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of multi drug resistance tuberculosis in Germany.
    Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
    Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation.
    Diel R; Vandeputte J; de Vries G; Stillo J; Wanlin M; Nienhaus A
    Eur Respir J; 2014 Feb; 43(2):554-65. PubMed ID: 23949960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
    Alemayehu S; Yigezu A; Hailemariam D; Hailu A
    PLoS One; 2020; 15(7):e0235820. PubMed ID: 32716915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
    Wolfson LJ; Walker A; Hettle R; Lu X; Kambili C; Murungi A; Knerer G
    PLoS One; 2015; 10(3):e0120763. PubMed ID: 25794045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.
    Floyd K; Hutubessy R; Kliiman K; Centis R; Khurieva N; Jakobowiak W; Danilovits M; Peremitin G; Keshavjee S; Migliori GB
    Eur Respir J; 2012 Jul; 40(1):133-42. PubMed ID: 22362862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 13. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
    Fitzpatrick C; Floyd K
    Pharmacoeconomics; 2012 Jan; 30(1):63-80. PubMed ID: 22070215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of decentralised care model for managing MDR-TB in India.
    John D; Chatterjee P; Murthy S; Bhat R; Musa BM
    Indian J Tuberc; 2018 Jul; 65(3):208-217. PubMed ID: 29933862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of multidrug resistant tuberculosis in Germany-An update.
    Diel R; Sotgiu G; Andres S; Hillemann D; Maurer FP
    Int J Infect Dis; 2021 Feb; 103():102-109. PubMed ID: 33157286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
    Laurence YV; Griffiths UK; Vassall A
    Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
    BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol.
    Gama E; Madan J; Langley I; Girma M; Evans D; Rosen S; Squire SB
    BMJ Open; 2016 Oct; 6(10):e014386. PubMed ID: 27798041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis: cost of illness in Germany.
    Diel R; Rutz S; Castell S; Schaberg T
    Eur Respir J; 2012 Jul; 40(1):143-51. PubMed ID: 22267754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis.
    Dowdy DW; van't Hoog A; Shah M; Cobelens F
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):647-54. PubMed ID: 24903933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.